Today, Lucerna announced the launch of the newest member in its fluorophore product line, OBI (3,5-difluoro-4-hydroxybenzylidene-imidazolinone-2-oxime-1-benzoimidazole). A derivative of BI, OBI exhibits enhanced stability to Red Broccoli™…
Category: Press Releases
On Thursday, May 28th, 2020, Lucerna will be giving a virtual talk to present the latest advances in its high-throughput RNA splicing drug discovery platform at the…
Today, Lucerna announced the launch of the newest member in its fluorophore product line, DFHBI-BI or BI. A derivative of DFHBI, BI is the first photostable green…
Lucerna has received a 1 year $225K SBIR Phase I grant from the National Institute of Allergy and Infectious Diseases to develop new high-throughput screening (HTS)…
Lucerna has received a 2 year $1.5M SBIR Phase II contract from the National Cancer Institute to develop new R&D tools to enable scientists to better…
Lucerna has been selected as a Innovate AveNew participant, a prestigious designation as one of the most promising emerging companies at the 2020 Society of Laboratory Automation…